An interventional study of Accu-Chek® Solo micropump system and mylife™ OmniPod® Insulin Management System in Diabetes Mellitus, Type 1, sponsored by Hoffmann-La Roche. Completed at 21 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-08-20.
Sponsored by Hoffmann-La Roche · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Diabetes Mellitus, Type 1 by Hoffmann-La Roche — 1 open to participants now, 1 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Hoffmann-La Roche.
Among the 15 studies in Diabetes Mellitus, Type 1 by Hoffmann-La Roche, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 13 with no phase, and was the 12th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →1 of the 15 studies in Diabetes Mellitus, Type 1 by Hoffmann-La Roche is open now, in 2 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Poland, Turkey
Ages 18+
By country, each count listing its studies:
Of the 415 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 65 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2018.
This study's enrollment of 181 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 80 across the 15 interventional studies. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Diabetes Mellitus, Type 1 by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This interventional device study aims to compare mainly standard Multiple Daily Injection (MDI) therapy vs. Accu-Chek® Solo Micropump System and investigates participant satisfaction. In addition, a third arm is included to compare to only similar product on the market which is OmniPod. The third arm is for data collection purpose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Continuous subcutaneous insulin infusion (CSII) with Accu-Chek® Solo Micropump system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
Device: Accu-Chek® Solo micropump system
Multiple daily injections (MDI) for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
Device: Accu-Chek® Solo micropump system · Other: Multiple Daily Injections (MDI) therapy
Continuous subcutaneous insulin infusion (CSII) with the mylife™ OmniPod® Insulin Management system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
Device: Accu-Chek® Solo micropump system · Device: mylife™ OmniPod® Insulin Management System
Medical device for subcutaneous delivery of insulin in a personalized way.
A patch pump system delivering insulin.
Injecting insulin as per participant's need.
Treatment Satisfaction: Accu-Chek® Micropump System vs. MDI, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score
The two comparisons will be performed using a hierarchical procedure. First, the comparison between the Accu-Chek® Solo system vs. MDI will be performed and only if the corresponding Null hypothesis of no difference between both systems can be rejected, then the second comparison between Accu-Chek® Solo system and versus mylife™ OmniPod® will also be performed. The DTQ questionnaire consists of 30 questions with the individual Change Scores ranging from 1 to 5, where 1 represents 'Much worse' and 5 represents 'Much better'. The Total Change Score Range on this questionnaire is from 30 to 150 with higher scores representing lower impairment and improved outcomes.
Time frame: 26 weeks
Treatment Satisfaction: Accu-Chek® Micropump System vs. Mylife™ OmniPod®, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score
The two comparisons will be performed using a hierarchical procedure. First, the comparison between the Accu-Chek® Solo system vs. MDI will be performed and only if the corresponding Null hypothesis of no difference between both systems can be rejected, then the second comparison between Accu-Chek® Solo system and versus mylife™ OmniPod® will also be performed. The DTQ questionnaire consists of 30 questions with the individual Change Scores ranging from 1 to 5, where 1 represents 'Much worse' and 5 represents 'Much better'. The Total Change Score Range on this questionnaire is from 30 to 150 with higher scores representing lower impairment and improved outcomes.
Time frame: 26 weeks
Diabetes-Related Emotional Distress Assessed by Problem Areas in Diabetes Scale (PAID)-5
The PAID-5 questionnaire consisted of 5 questions with answers ranging from 0 (not a problem) to 4 (serious problem). The total score was calculated as the sum of the individual questions, resulting in a number between 0 and 20 where lower scores represented lower distress.
Time frame: Week 26 up to Week 39
Device Satisfaction and Treatment Preference
Device Satisfaction and Treatment Preference was the main focus of part 2 questions of the DTQ. This part of the DTQ questionnaire consisted of individual sections with 9 questions each for the Blood Glucose Meter and Insulin Pump. Individual scores ranged from 1 (terrible) to 5 (excellent). Thus, the resulting sum score ranged from 9 to 45 for each type of device.
Time frame: Baseline up to Week 39
Therapy Success Confirmed by Glycated Hemoglobin (Hb1Ac) Levels
Change in Glycated Haemoglobin (HbA1c) Levels from Baseline to Week 39
Time frame: Baseline up to Week 39
Therapy Success Indicated by Change in Body Mass Index (BMI)
This outcome measure represents one reported value calculated by combining weight and height to report BMI in kg/m\^2. Change in BMI from Baseline to Week 39.
Time frame: Baseline up to Week 39
Therapy Success Indicated by Change in Weight
Change in Weight from Baseline to Week 39
Time frame: Baseline up to Week 39
Change in Glycemic Index
Change in Glycemic Index from Baseline to Week 39
Time frame: Baseline up to Week 39
Number of Participants With Therapy Parameters Indicated by Commencement of Continuous Subcutaneous Insulin Infusion (CSII)
Continuous Subcutaneous Insulin Infusion (CSII) therapy is also referred to as Insulin Pump Therapy. Presented below, are the Number of Participants for whom certain indications e.g. HbA1c goals not met, resulted in commencement of CSII therapy.
Time frame: Baseline up to Week 39
Change in Therapy Parameters Based on Type of Insulin Used
Time frame: Baseline up to Week 39
Change in Therapy Parameters Indicated by Total Daily Insulin Dose (TDD)
Total Daily Insulin Dose at Baseline compared to dose at Week 39
Time frame: Baseline up to Week 39
Change in Therapy Parameters Indicated by Total Daily Basal Insulin Dose (TBD)
Total Daily Basal Insulin Dose at Baseline compared to dose at Week 39
Time frame: Baseline up to Week 39
Change in Therapy Parameters Based on Average Number of Self Monitoring of Blood Glucose (SMBGs) Per Day
Average Number of Self Monitoring of Blood Glucose (SMBGs) per day from Baseline up to Week 39
Time frame: Baseline up to Week 39
Percentage of Time Spent in Hypoglycaemic Blood Glucose (BG) Ranges
Change in Frequency of Hypoglycaemic Events are reported below as the percentage of time spent in hypoglycaemic blood glucose (BG) ranges.
Time frame: Baseline up to Week 39
Percentage of Time Spent in Hyperglycaemic Blood Glucose (BG) Ranges
Change in Frequency of Hyperglycaemic Events are reported below as the percentage of time spent in hyperglycaemic blood glucose (BG) ranges.
Time frame: Baseline up to Week 39
Number of Consultations
Consultations between scheduled visits, emergency and call center calls, hospitalizations and absenteeism from work/school.
Time frame: Baseline up to Week 39
Number of Pods/Infusion Assemblies Falling Off Prematurely
Time frame: Baseline up to Week 39
Average Time Spent on Infusion Assembly
Time frame: Baseline up to Week 39
Number of Participants With Skin Reactions (Including Type and Intensity)
Number of Participants who experienced Skin Reactions at the Insulin Pump Insertion Sites (along with their Type and Intensity) are presented below, from Baseline up to Week 39. Participants were asked to assess five different properties describing potential problems at the pump insertion site, namely "itching", "redness", "swelling", "heat" and "pain". Each of these questions could be answered with one of four alternatives, "None", "Minor", "Moderate" and "Severe".
Time frame: Baseline up to Week 39
Socio-economic Acceptance: Amount of Insulin Left in Device at Reservoir Change/Device Discard
Time frame: Baseline up to Week 39
Amount of Waste, Inferred by Total Material Consumption
Time frame: Baseline up to Week 39
The study was conducted at 21 centers in 4 countries.
| Milestone | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| Started | 62 | 61 | 58 |
| Participants at end of parallel phase | 55 | 58 | 52 |
| Completed | 53 | 49 | 40 |
| Not completed | 9 | 12 | 18 |
| Withdrew: Withdrawal by subject | 4 | 7 | 6 |
| Withdrew: Adverse event | 2 | 0 | 1 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
| Withdrew: Personal reasons | 1 | 0 | 1 |
| Withdrew: Covid-19 | 1 | 4 | 3 |
| Withdrew: Multiple reasons | 0 | 1 | 1 |
| Withdrew: Eligibility criteria | 0 | 0 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
The two comparisons will be performed using a hierarchical procedure. First, the comparison between the Accu-Chek® Solo system vs. MDI will be performed and only if the corresponding Null hypothesis of no difference between both systems can be rejected, then the second comparison between Accu-Chek® Solo system and versus mylife™ OmniPod® will also be performed. The DTQ questionnaire consists of 30 questions with the individual Change Scores ranging from 1 to 5, where 1 represents 'Much worse' and 5 represents 'Much better'. The Total Change Score Range on this questionnaire is from 30 to 150 with higher scores representing lower impairment and improved outcomes.
| Scores on a Scale | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo |
|---|---|---|
| Treatment Satisfaction: Accu-Chek® Micropump System vs. MDI, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score | 105.9 ± 2.66 | 94.8 ± 2.63 |
The two comparisons will be performed using a hierarchical procedure. First, the comparison between the Accu-Chek® Solo system vs. MDI will be performed and only if the corresponding Null hypothesis of no difference between both systems can be rejected, then the second comparison between Accu-Chek® Solo system and versus mylife™ OmniPod® will also be performed. The DTQ questionnaire consists of 30 questions with the individual Change Scores ranging from 1 to 5, where 1 represents 'Much worse' and 5 represents 'Much better'. The Total Change Score Range on this questionnaire is from 30 to 150 with higher scores representing lower impairment and improved outcomes.
| Scores on a Scale | Group A: Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|
| Treatment Satisfaction: Accu-Chek® Micropump System vs. Mylife™ OmniPod®, Measured by the Difference in the Diabetes Technology Questionnaire (DTQ) Total Change Score | 105.1 ± 3.04 | 108.7 ± 2.85 |
The PAID-5 questionnaire consisted of 5 questions with answers ranging from 0 (not a problem) to 4 (serious problem). The total score was calculated as the sum of the individual questions, resulting in a number between 0 and 20 where lower scores represented lower distress.
| Scores on a Scale | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| Week 26 | 7.0 ± 4.7 | 7.8 ± 4.3 | 5.3 ± 3.5 |
| Week 39 | 6.3 ± 4.2 | 7.1 ± 4.5 | 5.8 ± 3.8 |
Device Satisfaction and Treatment Preference was the main focus of part 2 questions of the DTQ. This part of the DTQ questionnaire consisted of individual sections with 9 questions each for the Blood Glucose Meter and Insulin Pump. Individual scores ranged from 1 (terrible) to 5 (excellent). Thus, the resulting sum score ranged from 9 to 45 for each type of device.
| Scores on a Scale | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| Screening (Blood Glucose Meter) | 35.3 ± 5.7 | 33.8 ± 5.4 | 35.7 ± 5.0 |
| Week 13 (Blood Glucose Meter) | 34.9 ± 6.1 | 34.0 ± 5.6 | 34.9 ± 5.5 |
| Week 26 (Blood Glucose Meter) | 34.3 ± 6.1 | 33.8 ± 5.1 | 34.9 ± 6.1 |
| Week 39 (Blood Glucose Meter) | 34.7 ± 7.3 | 34.5 ± 5.8 | 34.8 ± 5.8 |
| Week 13 (Insulin Pump) | 32.7 ± 7.3 | — | 35.3 ± 4.9 |
| Week 26 (Insulin Pump) | 33.4 ± 6.6 | — | 35.3 ± 5.1 |
| Week 39 (Insulin Pump) | 33.4 ± 6.9 | 33.8 ± 6.3 | 31.0 ± 7.0 |
Change in Glycated Haemoglobin (HbA1c) Levels from Baseline to Week 39
| Percentage | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| HbA1c at Baseline | 8.0 ± 0.6 | 8.0 ± 0.5 | 8.0 ± 0.6 |
| HbA1c after 13 weeks | 7.8 ± 0.8 | 8.0 ± 0.6 | 7.9 ± 0.9 |
| HbA1c after 26 weeks | 7.9 ± 0.9 | 8.2 ± 0.7 | 7.9 ± 0.9 |
| HbA1c after 39 weeks | 7.8 ± 0.9 | 8.2 ± 1.1 | 8.1 ± 0.9 |
This outcome measure represents one reported value calculated by combining weight and height to report BMI in kg/m\^2. Change in BMI from Baseline to Week 39.
| kg/m^2 | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| Baseline | 25.4 ± 3.5 | 27.1 ± 4.7 | 27.0 ± 5.2 |
| Week 13 | 25.3 ± 3.5 | 27.1 ± 4.7 | 27.0 ± 5.2 |
| Week 26 | 25.4 ± 3.5 | 27.3 ± 5.0 | 27.3 ± 5.0 |
| Week 39 | 25.7 ± 3.4 | 27.4 ± 5.0 | 27.3 ± 5.2 |
Change in Weight from Baseline to Week 39
| kg | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| Baseline | 77.2 ± 14.1 | 81.7 ± 17.7 | 83.4 ± 18.1 |
| Week 13 | 77.6 ± 14.3 | 82.3 ± 18.0 | 83.8 ± 17.2 |
| Week 26 | 78.4 ± 14.9 | 82.2 ± 18.2 | 84.3 ± 17.4 |
| Week 39 | 78.8 ± 14.6 | 82.4 ± 18.2 | 81.8 ± 17.1 |
Change in Glycemic Index from Baseline to Week 39
| mg/dL | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| Baseline to Week 13 | 77.0 ± 15.0 | 71.7 ± 15.6 | 68.1 ± 10.2 |
| Week 13 to Week 26 | 75.0 ± 21.6 | 70.2 ± 13.1 | 68.9 ± 10.0 |
| Week 26 to Week 39 | 75.0 ± 17.0 | 73.9 ± 15.2 | 77.1 ± 15.2 |
Continuous Subcutaneous Insulin Infusion (CSII) therapy is also referred to as Insulin Pump Therapy. Presented below, are the Number of Participants for whom certain indications e.g. HbA1c goals not met, resulted in commencement of CSII therapy.
| Participants | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| HbA1c goals not met | 62 | 61 | 56 |
| Participant wish | 47 | 45 | 32 |
| Frequent hypoglycemia | 9 | 9 | 13 |
| Dawn phenomenon | 3 | 2 | 2 |
| Glycemic variability | 1 | 3 | 2 |
| Shift working | 1 | 0 | 1 |
| U/kg | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| Short Acting Insulin: Insulin aspart (Screening) | 37 | 30 | 39 |
| Short Acting Insulin: Insulin glulisine (Screening) | 2 | 9 | 2 |
| Short Acting Insulin: Insulin lispro (Screening) | 21 | 22 | 17 |
| Short Acting Insulin: Regular human insulin (Screening) | 2 | 0 | 0 |
| Long Acting Insulin: Insulatard (Screening) | 1 | 1 | 0 |
| Long Acting Insulin: Insulin degludec (Screening) | 9 | 9 | 13 |
| Long Acting Insulin: Insulin detemir (Screening) | 10 | 12 | 13 |
| Long Acting Insulin: Insulin glargine (Screening) | 42 | 38 | 32 |
| Long Acting Insulin: Protaphane (Screening) | 0 | 1 | 0 |
| Short Acting Insulin: Insulin aspart (Week 13) | 34 | 11 | 32 |
| Short Acting Insulin: Insulin glulisine (Week 13) | 2 | 5 | 0 |
| Short Acting Insulin: Insulin lispro (Week 13) | 20 | 9 | 20 |
| Long Acting Insulin: Insulin degludec (Week 13) | 0 | 3 | — |
| Long Acting Insulin: Insulin detemir (Week 13) | 0 | 8 | — |
| Long Acting Insulin: Insulin glargine (Week 13) | 1 | 14 | — |
| Short Acting Insulin: Insulin aspart (Week 26) | 34 | 20 | 32 |
| Short Acting Insulin: Insulin glulisine (Week 26) | 2 | 7 | 0 |
| Short Acting Insulin: Insulin lispro (Week 26) | 19 | 16 | 20 |
| Short Acting Insulin: NovoRapid (Week 26) | 0 | 1 | 0 |
| Long Acting Insulin: Insulin degludec (Week 26) | 0 | 10 | — |
| Long Acting Insulin: Insulin detemir (Week 26) | 0 | 9 | — |
| Long Acting Insulin: Insulin glargine (Week 26) | 1 | 25 | — |
| Short Acting Insulin: Insulin aspart (Week 39) | 36 | 27 | 32 |
| Short Acting Insulin: Insulin glulisine (Week 39) | 2 | 8 | 0 |
| Short Acting Insulin: Insulin lispro (Week 39) | 22 | 22 | 21 |
| Long Acting Insulin: Insulin degludec (Week 39) | 3 | 1 | 0 |
| Long Acting Insulin: Insulin detemir (Week 39) | 1 | 3 | 2 |
| Long Acting Insulin: Insulin glargine (Week 39) | 0 | 3 | 2 |
Total Daily Insulin Dose at Baseline compared to dose at Week 39
| U/kg | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| Screening | 0.7 ± 0.2 | 0.6 ± 0.2 | 0.7 ± 0.2 |
| Week 13 | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 |
| Week 26 | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 |
| Week 39 | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 |
Total Daily Basal Insulin Dose at Baseline compared to dose at Week 39
| U/kg | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| Screening | 0.3 ± 0.1 | 0.3 ± 0.1 | 0.3 ± 0.1 |
| Week 13 | 0.3 ± 0.1 | 0.3 ± 0.1 | 0.2 ± 0.1 |
| Week 26 | 0.3 ± 0.1 | 0.3 ± 0.1 | 0.3 ± 0.1 |
| Week 39 | 0.3 ± 0.1 | 0.3 ± 0.1 | 0.3 ± 0.1 |
Average Number of Self Monitoring of Blood Glucose (SMBGs) per day from Baseline up to Week 39
| SMBGs per day | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| Change in Therapy Parameters Based on Average Number of Self Monitoring of Blood Glucose (SMBGs) Per Day | 3.2 ± 3.0 | 3.4 ± 3.8 | 2.5 ± 3.1 |
Change in Frequency of Hypoglycaemic Events are reported below as the percentage of time spent in hypoglycaemic blood glucose (BG) ranges.
| Percentage of Time Spent | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| <54 mg/dL (Baseline to Week 13) | 3.0 ± 7.5 | 1.6 ± 2.1 | 1.1 ± 1.9 |
| <54 mg/dL (Week 13 to Week 26) | 1.8 ± 3.5 | 1.6 ± 1.9 | 0.9 ± 2.1 |
| <54 mg/dL (Week 26 to Week 39) | 1.7 ± 2.2 | 0.8 ± 1.1 | 1.1 ± 2.9 |
| >=54 and <70 mg/dL (Baseline to Week 13) | 5.8 ± 6.5 | 4.5 ± 3.0 | 3.1 ± 5.6 |
| >=54 and <70 mg/dL (Week 13 to Week 26) | 4.9 ± 6.2 | 4.2 ± 4.2 | 3.2 ± 4.5 |
| >=54 and <70 mg/dL (Week 26 to Week 39) | 5.6 ± 5.5 | 3.0 ± 3.1 | 1.4 ± 2.0 |
| <70 mg/dL (Baseline to Week 13) | 8.8 ± 9.4 | 6.1 ± 4.7 | 4.2 ± 6.2 |
| <70 mg/dL (Week 13 to Week 26) | 6.7 ± 8.8 | 5.8 ± 5.1 | 4.1 ± 4.8 |
| <70 mg/dL (Week 26 to Week 39) | 7.3 ± 6.8 | 3.8 ± 3.7 | 2.5 ± 3.5 |
Change in Frequency of Hyperglycaemic Events are reported below as the percentage of time spent in hyperglycaemic blood glucose (BG) ranges.
| Percentage of Time Spent | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| >180 to <250 mg/dL (Baseline to Week 13) | 19.3 ± 11.0 | 25.9 ± 9.0 | 26.4 ± 11.4 |
| >180 to <250 mg/dL (Week 13 to Week 26) | 19.3 ± 12.6 | 25.5 ± 7.9 | 25.4 ± 12.1 |
| >180 to <250 mg/dL (Week 26 to Week 39) | 20.3 ± 8.9 | 21.6 ± 10.1 | 26.6 ± 10.5 |
| >250 mg/dL (Baseline to Week 13) | 17.4 ± 10.4 | 19.5 ± 9.5 | 16.4 ± 12.4 |
| >250 mg/dL (Week 13 to Week 26) | 15.6 ± 12.5 | 18.9 ± 8.1 | 21.0 ± 15.5 |
| >250 mg/dL (Week 26 to Week 39) | 20.3 ± 19.3 | 26.8 ± 17.2 | 29.2 ± 16.7 |
Consultations between scheduled visits, emergency and call center calls, hospitalizations and absenteeism from work/school.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Number of Participants who experienced Skin Reactions at the Insulin Pump Insertion Sites (along with their Type and Intensity) are presented below, from Baseline up to Week 39. Participants were asked to assess five different properties describing potential problems at the pump insertion site, namely "itching", "redness", "swelling", "heat" and "pain". Each of these questions could be answered with one of four alternatives, "None", "Minor", "Moderate" and "Severe".
| Number of Participants | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo |
|---|---|---|---|
| Baseline (Itching) (Minor Intensity) | 2 | 1 | 1 |
| Baseline (Itching) (Moderate Intensity) | 0 | 0 | 0 |
| Baseline (Itching) (Severe Intensity) | 0 | 0 | 0 |
| Week 13 (Itching) (Minor Intensity) | 4 | 0 | 4 |
| Week 13 (Itching) (Moderate Intensity) | 2 | 0 | 1 |
| Week 13 (Itching) (Severe Intensity) | 0 | 0 | 1 |
| Week 26 (Itching) (Minor Intensity) | 6 | 2 | 2 |
| Week 26 (Itching) (Moderate Intensity) | 0 | 0 | 5 |
| Week 26 (Itching) (Severe Intensity) | 0 | 0 | 0 |
| Week 39 (Itching) (Minor Intensity) | 5 | 8 | 3 |
| Week 39 (Itching) (Moderate Intensity) | 0 | 3 | 3 |
| Week 39 (Itching) (Severe Intensity) | 1 | 0 | 2 |
| Baseline (Redness) (Minor Intensity) | 1 | 3 | 3 |
| Baseline (Redness) (Moderate Intensity) | 0 | 0 | 0 |
| Baseline (Redness) (Severe Intensity) | 0 | 0 | 0 |
| Week 13 (Redness) (Minor Intensity) | 8 | 4 | 11 |
| Week 13 (Redness) (Moderate Intensity) | 2 | 0 | 5 |
| Week 13 (Redness) (Severe Intensity) | 0 | 0 | 0 |
| Week 26 (Redness) (Minor Intensity) | 15 | 3 | 9 |
| Week 26 (Redness) (Moderate Intensity) | 0 | 0 | 4 |
| Week 26 (Redness) (Severe Intensity) | 0 | 0 | 0 |
| Week 39 (Redness) (Minor Intensity) | 16 | 11 | 10 |
| Week 39 (Redness) (Moderate Intensity) | 1 | 6 | 6 |
| Week 39 (Redness) (Severe Intensity) | 0 | 1 | 1 |
| Baseline (Swelling) (Minor Intensity) | 1 | 0 | 0 |
| Baseline (Swelling) (Moderate Intensity) | 1 | 0 | 0 |
| Baseline (Swelling) (Severe Intensity) | 0 | 0 | 0 |
| Week 13 (Swelling) (Minor Intensity) | 3 | 1 | 7 |
| Week 13 (Swelling) (Moderate Intensity) | 2 | 0 | 3 |
| Week 13 (Swelling) (Severe Intensity) | 0 | 0 | 0 |
| Week 26 (Swelling) (Minor Intensity) | 5 | 0 | 3 |
| Week 26 (Swelling) (Moderate Intensity) | 0 | 0 | 1 |
| Week 26 (Swelling) (Severe Intensity) | 0 | 0 | 0 |
| Week 39 (Swelling) (Minor Intensity) | 2 | 1 | 6 |
| Week 39 (Swelling) (Moderate Intensity) | 0 | 4 | 2 |
| Week 39 (Swelling) (Severe Intensity) | 0 | 0 | 0 |
| Baseline (Heat) (Minor Intensity) | 0 | 0 | 0 |
| Baseline (Heat) (Moderate Intensity) | 0 | 0 | 0 |
| Baseline (Heat) (Severe Intensity) | 0 | 0 | 0 |
| Week 13 (Heat) (Minor Intensity) | 1 | 0 | 3 |
| Week 13 (Heat) (Moderate Intensity) | 1 | 1 | 0 |
| Week 13 (Heat) (Severe Intensity) | 0 | 0 | 0 |
| Week 26 (Heat) (Minor Intensity) | 0 | 0 | 1 |
| Week 26 (Heat) (Moderate Intensity) | 0 | 0 | 1 |
| Week 26 (Heat) (Severe Intensity) | 0 | 0 | 0 |
| Week 39 (Heat) (Minor Intensity) | 1 | 1 | 1 |
| Week 39 (Heat) (Moderate Intensity) | 0 | 1 | 0 |
| Week 39 (Heat) (Severe Intensity) | 0 | 1 | 0 |
| Baseline (Pain) (Minor Intensity) | 4 | 3 | 3 |
| Baseline (Pain) (Moderate Intensity) | 0 | 0 | 2 |
| Baseline (Pain) (Severe Intensity) | 0 | 0 | 0 |
| Week 13 (Pain) (Minor Intensity) | 3 | 1 | 3 |
| Week 13 (Pain) (Moderate Intensity) | 1 | 1 | 2 |
| Week 13 (Pain) (Severe Intensity) | 1 | 0 | 0 |
| Week 26 (Pain) (Minor Intensity) | 3 | 3 | 3 |
| Week 26 (Pain) (Moderate Intensity) | 1 | 0 | 2 |
| Week 26 (Pain) (Severe Intensity) | 0 | 0 | 0 |
| Week 39 (Pain) (Minor Intensity) | 3 | 4 | 4 |
| Week 39 (Pain) (Moderate Intensity) | 1 | 1 | 3 |
| Week 39 (Pain) (Severe Intensity) | 0 | 2 | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over Baseline up until a maximum of 40 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: Accu-Chek® Solo (Parallel Phase) | 0/62 (0%) | 6/62 (9.7%) | 44/62 (71%) |
| Group B: MDI (Parallel Phase) | 0/61 (0%) | 1/61 (1.6%) | 35/61 (57.4%) |
| Group C: Mylife™ OmniPod® (Parallel Phase) | 0/58 (0%) | 5/58 (8.6%) | 35/58 (60.3%) |
| Group D: Groups A+B+C (Solo Phase) | 0/165 (0%) | 4/165 (2.4%) | 82/165 (49.7%) |
| Event | Group A: Accu-Chek® Solo (Parallel Phase) | Group B: MDI (Parallel Phase) | Group C: Mylife™ OmniPod® (Parallel Phase) | Group D: Groups A+B+C (Solo Phase) |
|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 3/62 | 1/61 | 1/58 | 2/165 |
| VomitingGastrointestinal disorders | 0/62 | 0/61 | 1/58 | 0/165 |
| Anaphylactic shockImmune system disorders | 0/62 | 0/61 | 1/58 | 0/165 |
| OsteomyelitisInfections and infestations | 0/62 | 0/61 | 1/58 | 0/165 |
| Arthropod biteInjury, poisoning and procedural complications | 0/62 | 0/61 | 1/58 | 0/165 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/62 | 0/61 | 1/58 | 0/165 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/62 | 0/61 | 1/58 | 0/165 |
| Diabetic KetosisMetabolism and nutrition disorders | 0/62 | 0/61 | 1/58 | 0/165 |
| Hypertensive crisisVascular disorders | 0/62 | 0/61 | 1/58 | 0/165 |
| AnaemiaBlood and lymphatic system disorders | 1/62 | 0/61 | 0/58 | 0/165 |
| Event | Group A: Accu-Chek® Solo (Parallel Phase) | Group B: MDI (Parallel Phase) | Group C: Mylife™ OmniPod® (Parallel Phase) | Group D: Groups A+B+C (Solo Phase) |
|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 32/62 | 28/61 | 22/58 | 49/165 |
| NasopharyngitisInfections and infestations | 5/62 | 7/61 | 9/58 | 12/165 |
| HyperglycaemiaMetabolism and nutrition disorders | 4/62 | 0/61 | 4/58 | 21/165 |
| Diabetic ketosisMetabolism and nutrition disorders | 3/62 | 0/61 | 0/58 | 0/165 |
| Age, Continuous(years) | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo | Total |
|---|---|---|---|---|
| Mean | 38.1 ± 11.8 | 38.6 ± 10.8 | 40.6 ± 13.1 | 39.0 ± 11.9 |
| Sex: Female, Male(Participants) | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo | Total |
|---|---|---|---|---|
| Female | 29 | 29 | 21 | 79 |
| Male | 33 | 32 | 37 | 102 |
| Race/Ethnicity, Customized(Participants) | Group A: Accu-Chek® Solo | Group B: MDI, Then Accu-Chek® Solo | Group C: Mylife™ OmniPod®, Then Accu-Chek® Solo | Total |
|---|---|---|---|---|
| White | 59 | 60 | 56 | 175 |
| Asian | 1 | 1 | 1 | 3 |
| Other | 2 | 0 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in May 2020, 24 months.
Results were first posted in Aug 2021, 1 year 2 months after primary completion.
Of 105 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 24 months is above that.
Counting every sponsor, half of 953 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.